Status:
WITHDRAWN
Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)
Lead Sponsor:
JW Pharmaceutical
Conditions:
Percutaneous Coronary Intervention
Eligibility:
All Genders
45-75 years
Phase:
PHASE4
Brief Summary
Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are meas...
Detailed Description
Procedural ischemic myocardial injury remains the most frequent complication after coronary angioplasty. Recently it was reported that pretreatment with atorvastatin reduce the myocardial damage compa...
Eligibility Criteria
Inclusion
- Patients with LDL ≥ 100mg/dL
- Patients who are scheduled an elective PCI for stable angina
Exclusion
- Acute myocardial infarction (\<3 months)
- Unstable angina
- Previous treatment with statins (\<6 months)
- Increase in CK-MB above upper normal limit
- Increase in liver enzymes (AST/ALT) above 2 times of upper normal limit
- Increase in serum creatinine above 2 times of upper normal limit
- Left ventricular ejection fraction \<30%
- Previous treatment with glycoprotein Ⅱb/Ⅲa receptor inhibitor (\<4 weeks)
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00786734
Start Date
August 1 2008
End Date
July 1 2010
Last Update
March 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic University of Korea Kangnam St. Mary's Hospital
Seoul, South Korea